Assessing the Impact of Cannabidiol on Seizure Frequency and Severity in Animal Models of Epilepsy

Epilepsy is a neurological disorder, leading to recurrent, unprovoked seizures. These seizures can vary in intensity and duration, affecting different parts of the brain. Epilepsy may result from various factors, including genetics, brain injuries, infections, or developmental issues. Current treatments options often have limited efficacy and significant side effects. Cannabidiol (CBD), a component of cannabis does not produce high, has shown promises for different pharmacological actions in preclinical studies. Study was undertaken to evaluate the antiepileptic efficacy of CBD in various animal models. 48 Wistar rats and 18 mice of both the sexes of weight 150-200 g & 40-50g respectively were used in the study. Two models maximal electroshock (MES) and Pentylenetetrazol (PTZ), were utilized to assess the anticonvulsant effects of CBD. Behavioural assessments was conducted to evaluate seizure frequency, severity, and potential neuroprotective effects. Statistical analysis done with graph pad prism 6. CBD administration produced significant reduction (p<0.001) in seizure frequency and severity in both the models. The dose-response relationship indicated that CBD has a broad therapeutic window with minimal side effects at effective doses. The findings suggest that CBD has anticonvulsant properties which was seen in the present study, supporting its potential as a safe and effective drug in treatment of epilepsy.